Novo Nordisk said Friday that its investigational anti-inflammatory drug did not reduce the risk of major heart events in a pivotal trial, raising questions about the increasingly popular approach of targeting inflammation to prevent cardiovascular complications.
In a Phase 3 study that enrolled over 6,300 people with heart disease, kidney disease, and inflammation, the drug, ziltivekimab, did lower markers of inflammation, Novo said. However, that did not translate into a reduction in risk of major complications, including cardiovascular-related death, heart attack, or stroke.
Novo shares were down about 7% Friday.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
